Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone
    Margulies, B. S.
    DeBoyace, S. D.
    Damron, T. A.
    Allen, M. J.
    BONE, 2015, 79 : 121 - 130
  • [32] NSG Mice Facilitate ex vivo Characterization of Ewing Sarcoma Lung Metastasis Using the PuMA Model
    Scopim-Ribeiro, Renata
    Lizardo, Michael M.
    Zhang, Hai-Feng
    Dhez, Anne-Chloe
    Hughes, Chistopher S.
    Sorensen, Poul H.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] Multimodal imaging of Ewing sarcoma in a preclinical model demonstrates the advantage of immunoPET
    Dearling, Jason
    Tupper, Tanya
    Modiste, Rebecca
    Dai, Guangping
    Quang-De Nguyen
    Kung, Andrew
    Packard, Alan
    O'Neill, Allison
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [34] Antitumor Vectorized Oligonucleotides in a Model of Ewing Sarcoma: Unexpected Role of Nanoparticles
    Elhamess, Hind
    Bertrand, Jean-Remi
    Maccario, Jean
    Maksimenko, Andrei
    Malvy, Claude
    OLIGONUCLEOTIDES, 2009, 19 (03) : 255 - 264
  • [35] Indoleamine-2,3-dioxygenase in an Immunotherapy Model for Ewing Sarcoma
    Max, Daniela
    Kuehnoel, Caspar D.
    Burdach, Stefan
    Niu, Liguo
    Staege, Martin S.
    Foell, Juergen L.
    ANTICANCER RESEARCH, 2014, 34 (11) : 6431 - 6441
  • [36] Tumor hypoxia promotes Ewing sarcoma metastases in a mouse xenograft model
    Tilan, Jason U.
    Hong, Sung-Hyeok
    Galli, Susana
    Acree, Rachel
    Connors, Katherine
    Horton, Meredith
    Mahajan, Akanksha
    Wietlisbach, Larissa
    Lee, Yi-Chien
    Rodriguez, Olga
    Albanese, Christopher
    Kitlinska, Joanna
    CANCER RESEARCH, 2016, 76
  • [37] The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation
    Hesketh, Anthony J.
    Maloney, Caroline
    Behr, Christopher A.
    Edelman, Morris C.
    Glick, Richard D.
    Al-Abed, Yousef
    Symons, Marc
    Soffer, Samuel Z.
    Steinberg, Bettie M.
    PLOS ONE, 2015, 10 (12):
  • [38] A Machine Learning-Based Predictive Model for Predicting Lymph Node Metastasis in Patients With Ewing's Sarcoma
    Li, Wenle
    Zhou, Qian
    Liu, Wencai
    Xu, Chan
    Tang, Zhi-Ri
    Dong, Shengtao
    Wang, Haosheng
    Li, Wanying
    Zhang, Kai
    Li, Rong
    Zhang, Wenshi
    Hu, Zhaohui
    Shibin, Su
    Liu, Qiang
    Kuang, Sirui
    Yin, Chengliang
    FRONTIERS IN MEDICINE, 2022, 9
  • [39] Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma
    Barlow, Meade
    Edelman, Morris
    Glick, Richard D.
    Steinberg, Bettie M.
    Soffer, Samuel Z.
    JOURNAL OF PEDIATRIC SURGERY, 2012, 47 (06) : 1223 - 1227
  • [40] Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics
    Khoury, Joseph D.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2008, 8 (01) : 97 - 104